Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy: A Systems Approach Phase 2 (ICAC-30)

Next Previous
Trial Profile

Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy: A Systems Approach Phase 2 (ICAC-30)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2018

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms MUPPITS-2

    • Most Recent Events

    • 01 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 10 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Oct 2017.
    • 27 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top